Rocket Pharmaceuticals Announces Results of 2026 Annual Meeting of Stockholders

On May 20, 2026, Rocket Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders. During the meeting, stockholders voted on four key proposals. First, the election of seven directors to the Board was approved, including Peter Fong, M.D., Carsten Boess, Mikael Dolsten, M.D., Ph.D., Fady Malik, M.D., Ph.D., Gaurav Shah, M.D., David P. Southwell, and Roderick Wong, M.D. Second, stockholders ratified the appointment of EisnerAmper LLP as the independent registered accounting firm for the fiscal year ending December 31, 2026. Third, a non-binding advisory vote approved the compensation of the company's named executive officers. Finally, stockholders approved a proposed stock option exchange program as detailed in the 2026 Proxy Statement. Approximately 74.02% of the total outstanding shares were represented at the meeting. No clinical data or regulatory updates were disclosed in this filing.